ইঙ্গিত
Rocuronium Hameln is used as an aid to general anesthesia. It helps facilitate tracheal intubation during routine induction, and also during rapid sequence induction when suxamethonium cannot be used. It provides skeletal muscle relaxation during surgery, and in the intensive care unit (ICU), it is used to aid intubation and mechanical ventilation.
⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।
ফার্মাকোলজি
Rocuronium acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Rocuronium acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur. Evidence also suggests that nondepolarizing agents can affect ACh release. It has been hypothesized that nondepolarzing agents bind to postjunctional ("curare") receptors and may therefore interfere with the sodium and potassium flux, which is responsible for depolarization and repolarization of the membranes involved in muscle contraction.
Pregnancy & Breastfeeding
Pregnancy: No clinical data are available on pregnancies exposed to Rocuronium Bromide. Animal studies have not shown any direct or indirect harmful effects on pregnancy, embryonal or foetal development, labour, or postnatal development. Even so, Rocuronium Bromide should be prescribed to pregnant women only with caution.
Caesarean section: Rocuronium Bromide can be used in patients undergoing Caesarean section as part of a rapid sequence induction, as long as no difficulty with intubation is expected and an adequate dose of anaesthetic agent is given, or after intubation has been facilitated with suxamethonium. A dose of 0.6 mg/kg has been shown to be safe in women undergoing Caesarean section, and it does not affect the Apgar score, foetal muscle tone, or cardio-respiratory adaptation. Sampling of umbilical cord blood shows that only a limited amount of Rocuronium Bromide crosses the placenta, and this does not result in any observable adverse effects in the newborn.
Lactation: Whether Rocuronium Bromide passes into human breast milk is not known. Animal studies have found only insignificant levels of the drug in breast milk, and, as with pregnancy, these studies have not shown any direct or indirect harmful effects on embryonal or foetal development, labour, or postnatal development. Rocuronium Bromide should be given to breastfeeding women only if the attending physician judges that the benefits outweigh the risks.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
ডোজ নির্দেশিকা
⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।
পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া
পার্শ্বপ্রতিক্রিয়া
No side-effect data recorded yet.